# Phase 1/2 brain cancer trials recruiting: 29 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 29 trials in phase 1/2 for brain cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 brain cancer trials: 29 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/brain-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 29
- Recruiting or not yet: 29
- Read on: November 19, 2026

## Trials

The 25 newest of 29, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 7, 2026 | NCT07751744 | Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal... | Jubilant Therapeutics Inc. | Phase 1/2 | Not yet recruiting | Brain Metastases From Solid Tumors, Leptomeningeal Disease, High Grade Glioma (HGG), Glioblastoma (GBM) | 113 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751744) |
| May 6, 2026 | NCT07569042 | A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma | Novelwise Pharmaceutical Corporation | Phase 1/2 | Recruiting | Malignant Neoplasm of Brain | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07569042) |
| February 18, 2026 | NCT07416188 | Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1/2 | Recruiting | Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Relapsed Cancer, Recurrent Tumor... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07416188) |
| October 3, 2025 | NCT07206498 | A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC | Wayshine Biopharm, Inc. | Phase 1/2 | Recruiting | Non Small Cell Lung Cancer (NSCLC) | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07206498) |
| September 17, 2025 | NCT07177950 | A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases | Peking University Cancer Hospital & Institute | Phase 1/2 | Not yet recruiting | Breast Cancer, Brain Metastases, Leptomeningeal Metastasis | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07177950) |
| April 2, 2025 | NCT06907043 | A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. | Eikon Therapeutics | Phase 1/2 | Recruiting | Advanced Solid Tumors | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06907043) |
| February 5, 2025 | NCT06810544 | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | Tango Therapeutics, Inc. | Phase 1/2 | Recruiting | Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor, Non-Small Cell... | 191 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06810544) |
| October 15, 2024 | NCT06640582 | TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas | Essen Biotech | Phase 1/2 | Recruiting | Brain Tumor, Brain Metastases, Brain Cancer, Glioma, Gliomas, Malignant, Glioblastoma, Meningioma | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06640582) |
| February 12, 2024 | NCT06253871 | A Phase 1/2 Study of IAM1363 in HER2 Cancers | Iambic Therapeutics, Inc | Phase 1/2 | Recruiting | HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer, Brain Metastases From Solid... | 463 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06253871) |
| February 5, 2024 | NCT06243003 | WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases | Fudan University | Phase 1/2 | Recruiting | SCLC,Extensive Stage, Brain Metastases | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06243003) |
| January 8, 2024 | NCT06194929 | Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma | University of Utah | Phase 1/2 | Recruiting | Cutaneous Melanoma, Brain Metastases | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06194929) |
| December 8, 2023 | NCT06161519 | PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | Glioma, Medulloblastoma, Ependymoma, Glioblastoma | 146 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06161519) |
| September 21, 2023 | NCT06047379 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Neonc Technologies, Inc. | Phase 1/2 | Recruiting | Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal... | 134 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06047379) |
| August 25, 2023 | NCT06012695 | NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma | Novelwise Pharmaceutical Corporation | Phase 1/2 | Recruiting | Malignant Neoplasm, Malignant Neoplasm of Brain | 79 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06012695) |
| August 14, 2023 | NCT05987644 | Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases... | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Lung Cancer, NSCLC, Brain Metastases | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05987644) |
| March 28, 2023 | NCT05786924 | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | Institut de Recherches Internationales Servier | Phase 1/2 | Recruiting | Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation... | 623 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05786924) |
| October 20, 2022 | NCT05588453 | Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma... | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05588453) |
| October 20, 2022 | NCT05588141 | 000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | Brain Tumor, Cancer | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05588141) |
| September 10, 2022 | NCT05535413 | UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases | Hunan Cancer Hospital | Phase 1/2 | Recruiting | Metastatic HER2 Negative Breast Carcinoma, Brain Metastases, Capecitabine, UDT1 | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05535413) |
| May 23, 2022 | NCT05386108 | Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | Stemline Therapeutics, Inc. | Phase 1/2 | Recruiting | Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms... | 73 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05386108) |
| February 25, 2022 | NCT05256290 | Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations | Black Diamond Therapeutics, Inc. | Phase 1/2 | Recruiting | Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma... | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05256290) |
| July 26, 2021 | NCT04977375 | Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Glioblastoma Multiforme | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04977375) |
| June 11, 2021 | NCT04923542 | SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases | H. Lee Moffitt Cancer Center and Research Institute | Phase 1/2 | Recruiting | Brain Metastases, HR+ Metastatic Breast Cancer | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04923542) |
| September 11, 2019 | NCT04085887 | Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures | Stanford University | Phase 1/2 | Recruiting | Brain Tumor | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04085887) |
| April 27, 2018 | NCT03510208 | Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery | Stanford University | Phase 1/2 | Recruiting | Malignant Brain Neoplasm, Malignant Glioma | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03510208) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Northwell Health | 2 |
| Novelwise Pharmaceutical Corporation | 2 |
| National Cancer Institute (NCI) | 2 |
| Stanford University | 2 |
| Eikon Therapeutics | 1 |
| Jubilant Therapeutics Inc. | 1 |
| University of Utah | 1 |
| Neonc Technologies, Inc. | 1 |
| Fudan University | 1 |
| Wayshine Biopharm, Inc. | 1 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 1 |
| Hunan Cancer Hospital | 1 |
| Peking University Cancer Hospital & Institute | 1 |
| Case Comprehensive Cancer Center | 1 |
| [Stemline Therapeutics, Inc.](https://specstream.ai/data/clinical-trials/company/stemline-therapeutics-inc) | 1 |
| H. Lee Moffitt Cancer Center and Research Institute | 1 |
| Black Diamond Therapeutics, Inc. | 1 |
| Weill Medical College of Cornell University | 1 |
| Tango Therapeutics, Inc. | 1 |
| Iambic Therapeutics, Inc | 1 |
| Institut de Recherches Internationales Servier | 1 |
| Essen Biotech | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 21 |
| China | 6 |
| France | 3 |
| Italy | 3 |
| Spain | 3 |
| United Kingdom | 3 |
| Australia | 2 |
| Taiwan | 2 |
| South Korea | 2 |
| Belgium | 1 |
| Germany | 1 |
| Greece | 1 |
| Turkey (Türkiye) | 1 |
| Canada | 1 |
| Ireland | 1 |
| Netherlands | 1 |
| Denmark | 1 |
| Hong Kong | 1 |
| Japan | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Urology practices in the United States](https://specstream.ai/data/businesses/urology-practices/united-states)
- [Mongolian restaurants in the United States](https://specstream.ai/data/businesses/mongolian-restaurants/united-states)
- [Dumpling restaurants in the United States](https://specstream.ai/data/businesses/dumpling-restaurants/united-states)
- [Wholesale florists in the United States](https://specstream.ai/data/businesses/wholesale-florists/united-states)
- [Orthopedics practices in the United States](https://specstream.ai/data/businesses/orthopedics-practices/united-states)
- [Environmental abatement companies in the United States](https://specstream.ai/data/businesses/environmental-abatement-companies/united-states)
